Employees Give High Marks for Their Co-Workers in San Francisco Business Times Competition

SANTA CLARA, Calif.–Affymetrix, Inc. (Nasdaq: AFFX – News) today was named “One of the Best Places to Work in the Bay Area” by the the San Francisco Business Times. This year’s list recognizes Bay Area companies for their employee engagement, as measured by an independent survey of nearly 400 area businesses. Employees were asked to rate their companies on 10 areas including team effectiveness, feeling of value, trust in senior leaders, and overall job satisfaction.

Affymetrix employees rated the company the highest in the following areas: close and trusting relationships with coworkers, satisfaction with their current role, belief in the effectiveness of their managers, and belief in the effectiveness of their team.

Affymetrix’ mission is to revolutionize how the world benefits from genetic information. The company creates products that enable scientists to understand the complicated information stored within our DNA. Scientists use this information to explore the genetic causes of common and rare diseases, which in turn may lead to better treatments.

The importance of Affymetrix technology has been highlighted in more than 17,000 peer-reviewed studies. In February, scientists published three papers in Nature Genetics describing their use of the Affymetrix® Genome-Wide Human SNP Array 6.0 and the GeneChip® Human Mapping 500K Array Set to conduct large-scale gene association studies focused on demystifying the risk of heart attacks.

“Today’s independently gathered results show that Affymetrix offers a truly rewarding place to make a difference and help shape the lives of others through our technology. We are fortunate to have such a great group of people working at the company,” said Kevin King, president and CEO of Affymetrix. “We are very proud to be voted by staff as one of the top places to work in the Bay Area.”

About Affymetrix

Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research. They enable scientists to develop diagnostics which may support the tailoring of treatments for patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 17,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.

Forward-looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the agreement with the San Francisco Business Times discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.